MRC DiMeN Doctoral Training Partnership: Use of 3D skin models and patient-derived immune cells to elucidate the molecular mechanisms of skin detachment in severe drug-induced skin adverse reactions


   MRC DiMeN Doctoral Training Partnership

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities
Dr Dan Carr Prof Dean Naisbitt Prof A Dickinson  No more applications being accepted  Competition Funded PhD Project (Students Worldwide)

About the Project

Background:
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening skin adverse drug reactions which can be caused by a multitude of prescriptions drugs. Though rare, SJS/TEN has a high mortality rate (5-30%) and can have devastating long-term effects on survivors, including loss of vision.

SJS/TEN are immune-mediated reactions which are primarily characterised by keratinocyte death and wide-spread skin detachment. Significant research has been undertaken to understand the immunological mechanisms of SJS/TEN. However, little is understood of the pathogenesis of epidermal detachment and skin cell (keratinocyte) injury. Indeed, the reason why some individuals progress to SJS/TEN while others exhibit only mild rash-like symptoms is not known. To date, no physiologically applicable cell-based models of SJS/TEN exist with which to probe the molecular basis of the epidermal detachment. Understanding of this has the potential to identify novel therapeutic targets for the treatment of SJS/TEN. At present no targeted therapy exists.

Project description:
The project will expand on existing 2D cell-culture work by using 3D skin equivalents and human skin explants to investigate the molecular pathogenesis of epidermal detachment in SJS/TEN. This represents the first time that 3D skin models have been utilised for the purpose of SJS/TEN research.

We have identified a novel molecular pathway which is up-regulated by the pro-inflammatory cytokine tumour necrosis factor alpha (TNF-α) in SJS/TEN patient skin and has a key role in the breakdown of the dermal/ epidermal junction leading to epidermal detachment/ blistering. Using SJS/TEN and healthy patient serum, and conditioned media from activated, isolated patient T-cells you will treat-exposed keratinocyte cell-lines and 3D skin-equivalents and investigate and characterise how the TNF-α molecular pathway mediates epidermal detachment. Furthermore, you will investigate how novel targeted therapies can modulate the effect of TNF-α to alleviate epidermal detachment.

Research Training and Supervision
This studentship would provide a unique training opportunity to be trained both in vitro modelling, immunological cell assays and molecular biological techniques by a highly experienced supervisory team each with complementary research skills. You will work under the supervision of Dr Dan Carr (https://www.liverpool.ac.uk/translational-medicine/staff/daniel-carr/) (@daniel_f_carr) and Prof. Dean Naisbitt https://www.liverpool.ac.uk/translational-medicine/staff/dean-naisbitt/) (@ImmunoPharm) from the MRC Centre for Drug Safety Science (@CDSS_Liverpool) a world-renowned centre of excellence for drug safety research. The student gain experience of 2D and 3D skin cell culturing and modelling techniques, immune cell activation assays and a range of molecular biology techniques including western blotting, transcriptomic analysis and immunohistochemistry. The student would also be trained in the handling and analysis of human clinical samples for the purpose of biomarker analysis.

In addition, under the supervision of Prof. Anne Dickinson you will spend up to 3 months per year working in the state-of-the-art labs of Alcyomics Ltd in Newcastle (alcyomics,com) where you will work with pre-clinical human skin biopsy models in order to apply your understanding of the mechanisms characterised in skin equivalents and gain valuable experience working in a commercial research environment.

Benefits of being in the DiMeN DTP:
This project is part of the Discovery Medicine North Doctoral Training Partnership (DiMeN DTP), a diverse community of PhD students across the North of England researching the major health problems facing the world today. Our partner institutions (Universities of Leeds, Liverpool, Newcastle and Sheffield) are internationally recognised as centres of research excellence and can offer you access to state-of the-art facilities to deliver high impact research.
We are very proud of our student-centred ethos and committed to supporting you throughout your PhD. As part of the DTP, we offer bespoke training in key skills sought after in early career researchers, as well as opportunities to broaden your career horizons in a range of non-academic sectors.

Being funded by the MRC means you can access additional funding for research placements, international training opportunities or internships in science policy, science communication and beyond. See how our current DiMeN students have benefited from this funding here: http://www.dimen.org.uk/overview/student-profiles/flexible-supplement-awards

Further information on the programme and how to apply can be found on our website:
https://bit.ly/3lQXR8A
Biological Sciences (4) Medicine (26)

Funding Notes

iCASE Award: Industrial partnership project

Funded by the MRC for 3.5yrs, including a minimum of 3 months working within the industry partner.

Funding will cover UK tuition fees and an enhanced stipend (around £17,785) only. We aim to support the most outstanding applicants from outside the UK. We are able to offer a limited number of bursaries that will enable full studentships to be awarded to international applicants. These full studentships will only be awarded to exceptional quality candidates, due to the competitive nature of this scheme. Please read additional guidance here: https://bit.ly/3kPNjoJ

Studentships commence: 1st October 2020.
Good luck!


References

1) Carr DF, Wang CW, Bellón T, Ressel L, Nwikue G, Shrivastava V, Bergfeld W,
Jorgensen AL, Chung WH, Pirmohamed M. Serum and blister-fluid elevation and
decreased epidermal content of high-mobility group box 1 protein in drug-induced
Stevens-Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol. 2019
Jul;181(1):166-174.

2) Zhao Q, Alhilali K, Alzahrani A, Almutairi M, Amjad J, Liu H, Sun Y, Sun L,
Zhang H, Meng X, Gibson A, Ogese MO, Kevin Park B, Liu J, Ostrov DA, Zhang F,
Naisbitt DJ. Dapsone- and nitroso dapsone-specific activation of T cells from
hypersensitive patients expressing the risk allele HLA-B*13:01. Allergy. 2019
Aug;74(8):1533-1548.

3) Sullivan A, Wang E, Farrell J, Whitaker P, Faulkner L, Peckham D, Park BK,
Naisbitt DJ. β-Lactam hypersensitivity involves expansion of circulating and
skin-resident T(H)22 cells. J Allergy Clin Immunol. 2018 Jan;141(1):235-249.e8.

Open Days


Where will I study?


Project supervisors

Career overview

Dr Dan Carr studied for a BSc (Hons) in Physiology and Pharmacology at the University of Central Lancashire and an MSc in Molecular Pathology and Toxicology at the University of Leicester. He worked within the Safety Assessment Department at AstraZeneca in Alderley Edge, Cheshire, before returning to Leicester to complete a PhD in the Department of Cancer Studies and Molecular Medicine. Dr Carr held a postdoctoral position in the Department of Pharmacology and Therapeutics (later Molecular and Clinical Pharmacology) at the University of Liverpool, under the supervision of Professors Munir Pirmohamed and Kevin Park. In 2009, he moved to the newly established Wolfson Centre for Personalised Medicine at the University of Liverpool. He was awarded a Tenure-Track fellowship in 2013, confirmed as a Lecturer in Pharmacology in 2017, and became a Senior Lecturer in 2023.


Research interests

Dr Carr''s research focuses on severe cutaneous adverse drug reactions, particularly Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). These are rare, life-threatening skin blistering reactions caused by various prescribed drugs. His lab aims to identify predictive biomarkers for SJS/TEN, both circulatory and skin-specific, and has developed novel ex vivo models to gain mechanistic insights into the pathogenesis of these conditions. This research has led to the identification of valid therapeutic targets, which are being investigated as potential novel treatment strategies for reactions that currently lack targeted therapies. Dr Carr has established a network of national and international academic collaborators in dermatology and pathology, as well as connections with SJS/TEN survivors and patient advocates to facilitate research, particularly in obtaining biological samples. Additionally, Dr Carr has a long-standing interest in pharmacogenomics and is involved in projects aimed at identifying genetic markers related to pharmacokinetics, pharmacodynamics, and drug safety across various fields, including infectious diseases, neurology, and diabetes. These projects are conducted in collaboration with academia, industry, and regulatory bodies.

View Dr Dan Carr's profile 

Career overview

Professor Dean Naisbitt holds a BSc and a PhD and is currently employed as a Senior Lecturer in the MRC funded Centre for Drug Safety Science at the University of Liverpool. His research focuses on investigating and defining the relationship between the chemistry of antigen formation and the mechanisms that lead to aberrant T-cell-mediated immune responses in humans. Professor Naisbitt leads a research group consisting of 2 post-doctoral research fellows, 6 PhD students, and 1 research technician. His laboratory''s work complements the ongoing research in the Centre for Drug Safety Science, directed by Professor B. Kevin Park. Professor Naisbitt has made significant contributions to the field of drug safety science, particularly in understanding cellular mechanisms of hypersensitivity reactions to drugs and chemicals, the interactions of drugs with immune cells, and the evaluation of vaccine safety and immunogenicity of new modality drugs.


Research interests

Professor Naisbitt''s research focuses on the investigation and definition of the relationship between the chemistry of antigen formation and the mechanisms that lead to aberrant T-cell-mediated immune responses in humans. His research group is involved in several key areas, including the investigation of cellular mechanisms of hypersensitivity reactions to drugs and chemicals, the definition of the mechanisms by which drugs interact with immune cells, the evaluation of vaccine safety, and the assessment of the immunogenicity of new modality drugs. His laboratory contributes significantly to the ongoing research at the Centre for Drug Safety Science.

View Professor Dean Naisbitt's profile 

Prof A Dickinson's profile is coming soon

View other supervisors at University of Liverpool 

Search Suggestions

Search suggestions

Based on your current searches we recommend the following search filters.

Search Suggestions

PhD suggestions

Based on your current search criteria we thought you might be interested in these.